Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be conducted in two parts. Part 1 is non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled. Visit ClinicalTrials.gov for more details.
- Drug: ACE-083
For study details, please contact Amanda Cowsert:
- 18 years and older
- Left and right ankle dorsiflexion Medical Research Council (MRC) manual muscle testing (MMT) grade 4- to 4+, inclusive
- Females of childbearing potential must have negative urine pregnancy test prior to enrollment and use highly effective birth control methods during study participation and for 8 weeks following the last dose of ACE-083. Males must agree to use a condom during any sexual contact with females of childbearing potential while participating in the study and for 8 weeks following the last dose of ACE-083, even if he has undergone a successful vasectomy.
- Ability to adhere to the study visit schedule/procedures, and to understand and comply with protocol requirements
- Phase 1 and Phase 2 have specific eligibility requirements, contact the study team for more details
Additional criteria apply, please contact Amanda Cowsert:
Can be done from home
KeywordsCharcot-Marie Tooth, Charcot-Marie-Tooth disease, Neurology
Principal InvestigatorS.H. Subramony, MD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.